We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Portable Device Developed for Early-Stage Malaria Detection

By LabMedica International staff writers
Posted on 13 Jun 2018
Over 216 million people were infected with malaria in 2016, and 445,000 individuals died from the disease. More...
The key to solving this health crisis is early-stage diagnosis when malaria therapeutics are most effective.

There are two standard ways of diagnosing malaria, yet both have limitations. The first involves taking a blood sample from a person and looking at it underneath a microscope for red blood cells that have been infected with the malaria parasite. Another method are the rapid diagnostic tests.

Bioengineers at the University of Southern California (Los Angeles, CA, USA) have developed a portable, magneto-optic technology for early stage malaria diagnosis based on the detection of the malaria pigment, hemozoin. The portable optical diagnostics system (PODS) prototype detects a byproduct generated by all species of the malaria parasite, as such; it is a rapid screening for all malaria strains. Because the amount of hemozoin in the blood is directly related to how far the malaria infection has progressed, it is an ideal indicator of infection.

By applying a magnet, it is possible to manipulate and move the hemozoin particles within a test tube around, or move them in and out of the laser beam. In this way, a single sample can be used to perform two measurements, and every diagnosis is personalized. If hemozoin is present, even in minute concentrations, the signals change. On average, it takes between 10 to 15 minutes for the signal to stabilize, and a larger difference between the two measurements indicates that the malaria has progressed farther. The scientists used β-hematin, a hemozoin mimic, and they demonstrated detection limits of less than 0.0081 μg/mL in 500 μL of whole rabbit blood with no additional reagents required. This level corresponds to less than 26 parasites/μL, a full order of magnitude below clinical relevance and comparable to or less than existing technologies.

Andrea Martin Armani, PhD, a professor of Chemical Engineering and Materials Science, and senior author of the study, said, “Malaria primarily impacts low-resource environments where supply chain management is difficult and access to power can be unreliable. Therefore, an effective malaria diagnostic must be independent of these.” The study was published on May 21, 2018, in the journal ACS Sensors.

Related Links:
University of Southern California


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Immunoassay Analyzer
Procise DX
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.